MedTrace Logo

Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs

NCT07436494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-02-27

No results posted yet for this study

Summary

The COVID-19 pandemic has caused significant psychological distress among patients with chronic diseases. Individuals receiving immunosuppressive therapies may experience increased anxiety due to perceived vulnerability to infection. This observational study aims to compare coronavirus-related anxiety levels in patients using biologic disease-modifying antirheumatic drugs (bDMARDs) and those using conventional disease-modifying antirheumatic drugs (cDMARDs).

Adult patients followed at the rheumatology outpatient clinic were contacted by telephone. After verbal consent was obtained, participants completed a patient information form and the Coronavirus Anxiety Scale. Anxiety levels and pandemic-related experiences were compared between treatment groups.

Conditions

Interventions

OTHER

Current treatment (no intervention assigned)

Participants are grouped based on their current prescribed DMARD regimen; no study intervention is administered.

Sponsors & Collaborators

  • Bursa City Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2021-01-15
Completion
2021-01-25

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07436494 on ClinicalTrials.gov